Affinity Asset Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Affinity Asset Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.81M	Hold	75,000	–	–	0.13%	94
2026 Q1	$2.72M	Hold	75,000	–	–	0.14%	88
2025 Q4	$3.49M	Hold	75,000	–	–	0.2%	71
2025 Q3	$3.12M	Sell	75,000 -77,252	-51%	-$2.47M	0.27%	64
2025 Q2	$4.38M	Hold	152,252	–	–	0.6%	44
2025 Q1	$5.11M	Sell	152,252 -307,748	-67%	-$11.5M	0.49%	42
2024 Q4	$23.5M	Buy	460,000 +60,000	+15%	+$3.36M	3.15%	9
2024 Q3	$20.4M	Sell	400,000 -115,000	-22%	-$5.93M	2.79%	9
2024 Q2	$23.1M	Buy	515,000 +45,000	+10%	+$2.08M	2.66%	7
2024 Q1	$22M	Buy	470,000 +22,905	+5%	+$896K	2.72%	7
2023 Q4	$15.9M	Sell	447,095 -2,905	-0.6%	-$89.1K	2.91%	10
2023 Q3	$13.4M	Buy	+450,000	New	+$9.27M	3.76%	7

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Affinity Asset Advisors's CRNX Position: Q2 2026 in Review

Affinity Asset Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 75,000 shares worth $2.81M. The position accounts for 0.13% of the portfolio, ranked #94.

Affinity Asset Advisors first reported a position in CRNX in Q3 2023 and has held it in 12 quarters since. The position peaked at $23.5M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Affinity Asset Advisors held 75,000 shares of Crinetics Pharmaceuticals worth $2.81M as of Q2 2026.
Affinity Asset Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up 0.13% of Affinity Asset Advisors's portfolio in Q2 2026, its #94 holding.
Affinity Asset Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Affinity Asset Advisors's Crinetics Pharmaceuticals position peaked at $23.5M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.